Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and iBio (NASDAQ:IBIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Whitehawk Therapeutics and iBio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| iBio | 1 | 0 | 4 | 3 | 3.12 |
Whitehawk Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 77.11%. iBio has a consensus price target of $5.00, suggesting a potential upside of 284.62%. Given iBio’s stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Whitehawk Therapeutics.
Volatility and Risk
Insider & Institutional Ownership
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Whitehawk Therapeutics and iBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| iBio | N/A | -40.66% | -35.78% |
Earnings and Valuation
This table compares Whitehawk Therapeutics and iBio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | $7.14 million | 36.97 | -$20.60 million | ($1.12) | -4.13 |
| iBio | $100,000.00 | 645.84 | -$33.04 million | ($0.34) | -3.82 |
Whitehawk Therapeutics has higher revenue and earnings than iBio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Summary
iBio beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
